Atrosimab

Synonyms: ATM-001
Atrosimab 是一种对人 EC50 值为 0.37 nM 的 Fv-Fc1K 融合蛋白,可抑制 TNF 诱导的 TNFR1 激活、IL-6 与 IL-8 释放及细胞死亡,并减轻神经炎症,可用于炎症性疾病、神经退行性疾病、急慢性炎症、实验性关节炎、非酒精性脂肪性肝炎及实验性自身免疫性脑脊髓炎的相关研究。
Atrosimab
产品编号: MS-X55442 纯度: 99% 分子量: 72.338 kDa
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Atrosimab 是一种对人 EC50 值为 0.37 nM 的 Fv-Fc1K 融合蛋白,可抑制 TNF 诱导的 TNFR1 激活、IL-6 与 IL-8 释放及细胞死亡,并减轻神经炎症,可用于炎症性疾病、神经退行性疾病、急慢性炎症、实验性关节炎、非酒精性脂肪性肝炎及实验性自身免疫性脑脊髓炎的相关研究。

生物实验数据

生物活性 Atrosimab is an Fv-Fc1K fusion protein with a human EC50 of 0.37 nM that inhibits TNF-induced TNFR1 activation, IL-6 and IL-8 release, and cell death while alleviating neuroinflammation, and it is applicable to research on inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis.
体外研究
(In Vitro)

Atrosimab (梯度稀释;4-128 nM) 可高亲和力结合纯化的人 TNFR1-Fc,且不与人补体蛋白 C1q 及人 Fcγ 受体 Ia、IIb、IIIa 结合。
Atrosimab (100 nM; 1, 3, 7 days) 在人血浆中可保持良好稳定性至少 7 天,且聚集温度为 64℃。
Atrosimab (系列稀释液;16-20 h, 24 h) 可强效抑制 TNF 介导的 HeLa、HT1080 和 Kym-1 细胞中 TNFR1 的激活,其 IC50 值分别为 54.5 nM、24.2 nM 和 16.2 nM。
Atrosimab (系列稀释处理;16-20 h) 在 HT1080 细胞中未表现出 TNFR1 激动活性,即便是经三种不同的山羊抗人 IgG 血清交联处理时。
Atrosimab (24 h) 孵育 24 小时后,对 huTNFR1-k/i 小鼠胚胎第 14 天原代皮质神经元的自发放电率或谷氨酸诱导的放电率改变均无影响。
Atrosimab (100 μg; heated from 35°C to 80°C with 2 min equilibration per 1°C interval; 2-500 nM; up to 9 months) 具有极强的热稳定性和长期稳定性,能够选择性地以高亲和力结合人、恒河猴及食蟹猴的 TNFR1 (但不结合小鼠/大鼠 TNFR1 或任何 TNFR2),并识别人 TNFR1 上一个包含 P23、L67、R68、H69 和 Q24 残基的表位。
Atrosimab (最高浓度 1000 nM;37℃、5% CO2 条件下处理 16-20 小时;37℃、50%人血清中孵育 1-7 天) 可强效且呈剂量依赖性地抑制 HT1080 细胞中 TNF 诱导的 IL-8 释放,对应的 IC50 值为 21.9-34.9 nM;该抗体在上述细胞中无激动活性,且在 37℃人血清中孵育长达 7 天后仍能维持功能稳定性。
Atrosimab (100 μg/mL; 24 h) 可在 hCMEC/D3 人脑微血管内皮细胞中抑制 TNF 诱导的 VCAM-1 和 ICAM-1 表达。

ELISA Assay

Cell Line: HT1080 cells
Concentration: serial dilutions of Atrosimab; ~15.8 nM (constant anti-human IgG serum)
Incubation Time: 16-20 h
Result: Showed no induction of IL-8 release across all tested concentrations, indicating no cross-linking-mediated TNFR1 agonistic activity.
体内研究
(In Vivo)

Atrosimab (3 μg; stereotactic co-injection into NBM) 可在 NMDA 诱导的急性神经退行性变小鼠模型中改善长期联想记忆,减少神经元及胆碱能神经元丢失,并降低胶质细胞活化水平与损伤面积。
Atrosimab (30 mg/kg; i.v.; single dose) 可强效阻断 huTNFR1-k/i 小鼠中由急性 TNF 诱导的炎症反应。
Atrosimab (20-80 mg/kg; s.c.; twice weekly; 11 weeks) 可在预防性给药模型中抑制关节炎的发生;Atrosimab (5-45 mg/kg; s.c.; twice weekly; 6 weeks) 在 Tg197hTNFR1KI 小鼠中可缓解已建立的关节炎,且疗效呈剂量依赖性。
Atrosimab (45 mg/kg; i.p.; twice weekly; 8 weeks) 可减轻 NASH 的 huTNFR1-k/i 小鼠模型中的肝纤维化、脂肪变性及凋亡损伤。
Atrosimab (30-60 mg/kg; i.p.; single doses on days 1, 4, 8, 12 of manifest disease) 可改善 huTNFR1-k/i 小鼠 EAE 模型中的运动症状、脱髓鞘及轴突损伤,其中 30 mg/kg 剂量即可发挥最大治疗活性。

Animal Model: huTNFR1-k/i (7-month-old male; C57Bl/6J background; NMDA-induced acute cholinergic neurodegeneration via stereotactic injection into NBM)
Dosage: 3 μg
Administration: stereotactic co-injection into NBM; infused at 0.1 μl/min at two dorsoventral depths: 0.3 μl at -0.44 mm and 0.3 μl at -0.46 mm relative to Bregma; total volume 0.6 μl
Result: Increased post-shock latency to 274.8 s in passive avoidance paradigm, indicating improved long-term associative memory.\nPrevented significant body weight loss, with mean body weight change of -2.43 g from surgery to perfusion.\nIncreased surface area of ChAT-positive cholinergic fibers in layer V of somatosensory cortex to 11.04%.\nIncreased ratio of cholinergic neurons in lesioned vs. non-lesioned NBM hemisphere to 0.14.\nIncreased ratio of NeuN-positive neuronal surface area in lesioned vs. non-lesioned somatosensory cortex layer V to 0.48.\nReduced volume of IBA-1-positive activated microglia/lesion size to 0.373 mm3.\nReduced ratio of CD68 mean intensity (lesioned vs. non-lesioned NBM hemisphere) to 1.22.\nReduced ratio of GFAP mean intensity (lesioned vs. non-lesioned NBM hemisphere) to 2.51. Showed no significant effect on short-term spatial memory, anxiety-like behavior, locomotor activity, or hippocampal synapsin-1 levels.
Animal Model: huTNFR1-k/i (C57BL/6 background)
Dosage: 30 mg/kg
Administration: i.v.; single dose
Result: Completely blocked TNF-induced body weight loss.\nSignificantly reduced serum IL-6 levels at 1 hour and 6 hours post-TNF injection to almost baseline levels.\nSignificantly reduced TNF-induced systemic CRP levels at 6 hours post-TNF injection compared to control-treated mice.
Animal Model: Tg197hTNFR1KI
Dosage: 20-80 mg/kg (prophylactic setting); 5-45 mg/kg (therapeutic setting)
Administration: s.c.; twice weekly; 11 weeks (prophylactic setting); 6 weeks (therapeutic setting)
Result: Prevented development of arthritic disease, prevented disease-associated inhibition of body weight gain, and resulted in no histopathological changes beyond the level of 4-week-old control mice (all doses, prophylactic setting).\nHalted disease progression (5 mg/kg, therapeutic setting).\nShowed improved therapeutic activity comparable to approved anti-TNF therapeutics (15 mg/kg, 45 mg/kg, therapeutic setting).\nImproved joint histopathology, with histopathological scores below the level of 9-week-old control mice (all doses, therapeutic setting).
Animal Model: huTNFR1-k/i (male)
Dosage: 45 mg/kg
Administration: i.p.; twice weekly; 8 weeks
Result: Significantly reduced liver fibrosis (assessed by Sirius Red staining).\nReduced liver steatosis (assessed by Oil Red O staining).\nDecreased activated caspase-3-positive cells (a marker of apoptotic liver injury) compared to saline-treated mice.
Animal Model: huTNFR1-k/i (female, 6-8 weeks old)
Dosage: 30-60 mg/kg
Administration: i.p.; single doses on days 1, 4, 8, 12 of manifest disease
Result: Ameliorated EAE motor symptoms.\nReduced cumulative EAE score.\nPrevented disease-associated weight loss.\nReduced cumulative weight loss.\nSignificantly reduced spinal cord demyelination (assessed by Luxol fast blue staining).\nSignificantly reduced axonal injury (assessed by amyloid precursor protein accumulation) compared to control-treated mice.\nShowed no efficacy difference between the 30 mg/kg and 60 mg/kg doses.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT04650126Baliopharm Pty Ltd
Healthy Volunteers
2021-07-12PHASE1
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 72.338 kDa
别名 ATM-001

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础